Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses

• Published in: International journal of oncology Vol. 28; no. 3; pp. 585 - 593
• Main Authors: Wei, Yanzhang, Sticca, Robert, Holmes, Lillia, Burgin, Kelly, Li, Jinhua, Williamson, Jane, Evans, Lyndon, Smith, Samuel, Stephenson, Joseph, Wagner, Thomas
• Format: Journal Article
• Language: English
• Published: Athens Editorial Academy of the International Journal of Oncology 01.03.2006
• Subjects: Adult; Aged; Biological and medical sciences; Cancer Vaccines - therapeutic use; CD4-Positive T-Lymphocytes - immunology; CD4-Positive T-Lymphocytes - metabolism; CD8-Positive T-Lymphocytes - immunology; CD8-Positive T-Lymphocytes - metabolism; Dendritic Cells - cytology; Dendritic Cells - immunology; Dermatology; Female; Flow Cytometry; Humans; Hybrid Cells - immunology; Hybrid Cells - transplantation; Immunotherapy, Adoptive - methods; Interferon-gamma - metabolism; Interleukin-2 - therapeutic use; Leukocytes, Mononuclear - immunology; Leukocytes, Mononuclear - pathology; Male; Medical sciences; Melanoma - immunology; Melanoma - pathology; Melanoma - therapy; Middle Aged; Neoplasm Metastasis; Pilot Projects; Skin Neoplasms - immunology; Skin Neoplasms - pathology; Skin Neoplasms - therapy; Treatment Outcome; Tumors; Tumors of the skin and soft tissue. Premalignant lesions; Human; clinical study; Dendritic cell; Low dose; Vaccination; Cytokine; melanoma; Malignant tumor; Metastasis; Prevention; fusion; Cancerology; Treatment; Interleukin 2; Antigen presenting cell; Immunotherapy; tumor; Malignant melanoma; Advanced stage; dendritoma

A pilot clinical trial using dendritomas, purified hybrids from the fusion of dendritic/tumor cells combined with a low dose of IL-2, in metastatic melanoma patients was conducted in order to determine its safety and potential immunological and clinical responses. Ten metastatic melanoma patients we...